CordovaCann Corp. operates in the cannabis sector, focusing on developing and managing operations within the cannabis value chain. The company shows a concerning financial health score of 11/100, highlighted by a low current ratio of 0.18, indicating liquidity issues. Despite a gross margin of 29.0%, the net margin is negative at -5.4%, raising concerns about profitability. The stock's recent decline of 16.67% further reflects market apprehension, suggesting investors should be cautious given the company's financial instability and low market cap of $2.75M.
Loading financial metrics...
Gross profit margin declined from 27.0% to 16.9% year-over-year, suggesting pricing pressure or rising input costs are squeezing profitability.
Company posted a loss of $-2.6M over the last year, representing 19.0% of revenue.
Debt of $5.2M is 10.0x the company's cash position of $515K.
No significant opportunities identified
Based on current financial metrics
Valuation, risk assessment, competitive positioning, and key insights — all in one report.
Other Drug Manufacturers - Specialty & Generic companies of a similar size
Based on 2026-Q3 (March 31, 2026)